Plain-English translation of NCT05967416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses your own immune cells that have been modified in the laboratory to help fight lymphoma. The treatment involves injecting these cells directly into a lymphoma tumor in your body, and some patients will also receive a small dose of radiation to the same area. The goal is to see if this approach is safe and whether it can help people with lymphoma that has come back or stopped responding to previous treatments.
Many people with lymphoma eventually find that standard treatments stop working, leaving them with limited options. Researchers are testing this medication because they believe directly injecting modified immune cells into tumors might be a better way to help the body fight back against this disease.
You likely qualify if…
You likely don't qualify if…
You would have cells collected from your blood in an outpatient procedure, which are then processed in the laboratory. You would then return for three injections of these modified cells given over a few days (either all in one week or spread over alternate days), and some participants will also receive focused radiation to the injected tumor site. Depending on how you respond, you may be eligible to receive a second round of treatment using cells from your initial collection. The trial will closely monitor your safety and how your lymphoma responds throughout the study.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States